Valuation: GlaxoSmithKline plc

Market Cap 7.07TCr 9.4TCr 8.34TCr 7.8TCr 13TCr 9,05700Cr 13TCr 94TCr 36TCr 4,62000Cr 35TCr 35TCr 14,85300Cr P/E 2026 *
13.7x
P/E 2027 * 11.3x
Enterprise Value 9.2TCr 12TCr 11TCr 10TCr 17TCr 11,77600Cr 17TCr 1,21900Cr 47TCr 6,00700Cr 46TCr 45TCr 19,31200Cr EV / Sales 2026 *
2.71x
EV / Sales 2027 * 2.52x
Free-Float
92.75%
Yield 2026 *
3.93%
Yield 2027 * 4.24%
Manager TitleAgeSince
Chief Executive Officer 52 01/01/2026
Director of Finance/CFO 64 01/05/2023
Compliance Officer - 01/08/2018
Director TitleAgeSince
Director/Board Member 52 06/05/2026
Director/Board Member 64 01/01/2018
Chairman 67 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
+1.26%-2.30%+37.82%+113.76% 1,01900Cr
+0.73%-6.31%+35.06%+62.14% 61TCr
+0.35%+0.15%+14.01%+80.87% 47TCr
+1.72%-4.54%+59.14%+37.01% 34TCr
+0.26%-1.58%+21.97%+41.79% 34TCr
+0.60%-3.48%+11.37%+34.33% 27TCr
+1.65%-4.27%-5.47%+9.69% 24TCr
-0.09%-3.71%+35.15%+51.88% 22TCr
-0.28%-5.24%+27.99%+93.08% 18TCr
Average +0.38%-3.63%+26.34%+58.28% 40.92TCr
Weighted average by Cap. +0.05%-3.51%+29.49%+70.06%

Financials

2026 *2027 *
Net sales 3.39TCr 4.5TCr 4TCr 3.74TCr 6.4TCr 4,34200Cr 6.45TCr 45TCr 17TCr 2,21500Cr 17TCr 17TCr 7,12000Cr 3.55TCr 4.71TCr 4.18TCr 3.92TCr 6.7TCr 4,54300Cr 6.75TCr 47TCr 18TCr 2,31800Cr 18TCr 17TCr 7,45100Cr
Net income 518.82Cr 689.04Cr 611.66Cr 572.4Cr 979.82Cr 66TCr 986.91Cr 6.87TCr 2.67TCr 34TCr 2.59TCr 2.53TCr 1,08900Cr 620.48Cr 824.06Cr 731.52Cr 684.56Cr 1.17TCr 79TCr 1.18TCr 8.22TCr 3.2TCr 41TCr 3.09TCr 3.03TCr 1,30300Cr
Net Debt 2.12TCr 2.82TCr 2.5TCr 2.34TCr 4.01TCr 2,71900Cr 4.04TCr 28TCr 11TCr 1,38700Cr 11TCr 10TCr 4,45900Cr 1.85TCr 2.46TCr 2.18TCr 2.04TCr 3.5TCr 2,37200Cr 3.52TCr 25TCr 9.55TCr 1,21000Cr 9.24TCr 9.04TCr 3,89000Cr
Logo GlaxoSmithKline plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - GlaxoSmithKline plc